DOI: 10.12890/2023_003792

Altitude pre-acclimatization with an erythropoiesis-stimulating agent

Authors

  • Micah Liam Arthur Heldeweg Department of internal medicine, Curaçao Medical Center, Willemstad, Curaçao
  • Jonathan Xavier Medina Feliz Department of Internal Medicine, Curaçao Medical Center, Willemstad, Curaçao
  • Kenrick Berend Department of internal medicine, Curaçao Medical Center, Willemstad, Curaçao

m.heldeweg@amsterdamumc.nl

Keywords

High altitude illness, erythropoiesis-stimulating agent, acclimatization

Abstract

Introduction: High altitude illness is a complication of rapid ascent above 2,500 m elevation. Ventilatory, circulatory and haematological adjustments, known as acclimatization, occur to maintain adequate delivery of oxygen. Although (non-)pharmaceutical strategies that modulate ventilation and circulation have long been accepted, the haematological approach has not.

Case description: This report describes the application of a comprehensive strategy, including prior pre-acclimatization using an erythropoiesis-stimulating agent (ESA), in two healthy subjects ascending from sea level to 6,268 m. Following ESA administration 30 days prior to ascent, the subjects had a cumulative haemoglobin rise of 7.1% and 11.9%, respectively. Both subjects experienced minimal symptoms during four incremental ascents to the final altitude and no adverse events occurred.

Discussion: This report has limited external validity, lacking both a sample size and controls, but can serve as practical exploration of the concept. Administration of an ESA may be a safe and useful pre-acclimatization strategy but cannot be recommended based on current evidence. More comprehensive research is needed.

View the entire article

Downloads

References

  1. Grocott MP, Martin DS, Levett DZ, McMorrow R, Windsor J, Montgomery HE; Caudwell Xtreme Everest Research Group. Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med 2009;360:140–149. doi: 10.1056/NEJMoa0801581
  2. Bärtsch P, Swenson ER. Clinical practice: acute high-altitude illnesses. N Engl J Med 2013;368:2294–2302. doi: 10.1056/NEJMcp1214870
  3. Dehnes Y, Hemmersbach P. Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parameters. Drug Test Anal 2011;3:291–299. doi: 10.1002/dta.270
  4. Lopez B. The invention of a 'drug of mass destruction': deconstructing the EPO myth. Sport in History 2011;31:84–109.
  5. Gupta N, Ashraf MZ. Exposure to high altitude: a risk factor for venous thromboembolism? Semin Thromb Hemost 2012;38:156–163. doi: 10.1055/s-0032-1301413
  6. Lundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol 2011;589:1265–1271. doi: 10.1113/jphysiol.2010.195917
  7. Heo K, Kang JK, Choi CM, Lee MS, Noh KW, Kim SB. Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial. J Korean Med Sci 2014;29:416–422. doi: 10.3346/jkms.2014.29.3.416

Published

2023-04-06

How to Cite

1.
Heldeweg MLA, Medina Feliz JX, Berend K. Altitude pre-acclimatization with an erythropoiesis-stimulating agent. EJCRIM [Internet]. 2023 Apr. 6 [cited 2026 Nov. 3];10(4). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3792

Most read articles by the same author(s)